96 results about "High-Fat Diets" patented technology

The invention provides a hypoglycemic peptide which is prepared by taking bovine whey protein as a raw material and is stable in gastrointestinal digestion and absorption. In an in-vitro cell experiment, the peptide fragment can improve the uptake of insulin-resistant HepG2 hepatocytes and synthesize glycogen by using glucose, can promote intestinal endocrine cells NCI-H716 to secrete GLP-1, has a certain synergistic effect, and can further play the effects of promoting GLP-1 secretion and activating a GLP-1 receptor through combined use. An insulin resistance mouse model is constructed by utilizing high-fat diet, and the peptide fragment is adopted for intervention, so that the hypoglycemic peptide is further proved to have obvious effects on losing weight, reducing lipid accumulation and assisting in reducing blood fat, and meanwhile, the hypoglycemic peptide can be used for improving insulin resistance related symptoms. The milk peptide provided by the invention has gastrointestinal digestion stability and hypoglycemic activity, can be used as a functional milk base material for developing food, medicines or health care products with the effect of regulating blood sugar, and is wide in application prospect.

The invention belongs to the field of medicines, and discloses application of pyroglutamic acid in preparation of products for inhibiting fat deposition. The invention has the following advantages: 1, obesity induced by high fat diet is prevented; 2, pyroglutamic acid is a natural amino acid derivative, widely exists in animal and plant bodies, and has good biological safety; meanwhile, the invention further discloses a product for inhibiting fat deposition.

The invention belongs to the field of microorganisms, and provides lactobacillus paracasei Jlus660321 with a function of assisting in reducing blood fat and cholesterol and application of the lactobacillus paracasei Jlus660321, and the preservation number of the lactobacillus paracasei Jlus660321 is CGMCC No. 33962. The lactobacillus paracasei Jlus 660321 has the functions of assisting in lowering blood fat and lowering cholesterol, shows excellent cholesterol lowering performance in a cholesterol degradation experiment, and can degrade 61.60% of cholesterol in the experiment. A hemolysis experiment result is gamma-hemolysis, namely, hemolysis is avoided, and toxic and side effects are small. Rat in-vivo experiments show that the lactobacillus paracasei Jlus 660321 can effectively slow down the increase of body weight, liver weight, liver index, low-density lipoprotein content and triglyceride content caused by high-fat diet, and further show that the lactobacillus paracasei Jlus 660321 has the function of assisting in reducing blood fat and cholesterol; the compound can be used for preparing medicines, nourishment or health care products for assisting in reducing blood fat and / or reducing cholesterol.

Disclosed is a strain of Bifidobacterium longum subsp. longum named dipro-O. The Bifidobacterium longum subsp. longum dipro-O used in the present invention has the ability to overproduce BSH, the ability to reduce cholesterol, and the ability to metabolize tryptophan into indole-3-lactic acid, can effectively reduce body weight, significantly lower insulin resistance levels resulting from high-fat diets, reduce the expression of the inflammatory cytokine TNF-α, significantly lower the levels of total cholesterol (TC) and low-density lipoprotein (LDL) in the blood, and increase the level of high-density lipoprotein (HDL), and can ameliorate disorders of the gut microbiome structure. In addition, the strain can also have an ameliorating effect on other lipid metabolism-related diseases such as hyperlipidemia, thereby providing health interventions for the host's body weight, liver, intestinal health, and blood lipid levels. Moreover, pasteurized dipro-O can also have the effect of regulating lipid metabolism, further extending the range of applications of the strain.

The invention discloses a composition for assisting in reducing blood sugar and blood fat as well as a preparation method and application thereof, and relates to the technical field of functional compositions. The composition comprises highland barley powder and modified inulin, the preparation method of the highland barley powder comprises the following steps: soaking highland barley grains in a weakly alkaline aqueous solution, and sequentially carrying out first pulse microwave treatment, enzyme deactivation treatment and segmented baking treatment; the segmented baking treatment comprises first-stage baking treatment and second-stage intermittent infrared irradiation treatment; the temperature of the first-stage baking treatment is 40-60 DEG C; the temperature of the second-stage intermittent infrared irradiation treatment is 60-80 DEG C, and the emission wavelength is 2.5-4 microns; the preparation method of the modified inulin comprises the following steps: performing acidolysis treatment on inulin in a weakly acidic aqueous solution, and then drying. The highland barley powder and the modified inulin in the embodiment can synergistically improve glycometabolism and lipid metabolism, effectively reduce the body weight, blood sugar, blood fat and the like under high-glucose and / or high-fat diet, and protect and repair the pancreas islet function.

The invention discloses pediococcus acidilactici for improving offspring social behaviors of a parent and application thereof, and belongs to the technical field of microorganisms. According to the pediococcus acidilactici CCFM1344 provided by the invention, by intervening neurodysplasia caused by high-fat diet of a parent body, the improvement of hyperactivity and social behaviors of the offspring is specifically shown as follows: (1) hyperactivity disorder, induced by high-fat diet of the parent body, of the offspring in juvenile and adult periods is recovered; (2) restoring parent high-fat diet induced social contact disorders of offspring juveniles and adult periods; (3) reducing the gene expression of the small glial cell M1 type differentiation marker CD86 in the offspring hippocampus; and (4) reducing the gene expression of the macrophage activation marker F4 / 80 in the offspring hippocampus. Through the probiotic preparation containing the pediococcus acidilactici CCFM1344, a new thought and method can be provided for early intervention of the autism spectrum disorder.

The invention provides application of quinoa seedling acidic polysaccharide or modified acidic polysaccharide thereof in preparation of drugs for improving lipid metabolism disorder or health-care food beneficial to maintaining the health level of blood fat. The invention further provides the quinoa seedling modified acidic polysaccharide and a preparation method thereof. According to the invention, the quinoa seedling acidic polysaccharide is subjected to structural modification, and by comparing the physical and chemical structural characteristics of the quinoa seedling acidic polysaccharide before and after modification and the health effect of improving lipid metabolism disorder, the quinoa seedling acidic polysaccharide and the modified acidic polysaccharide thereof are found to be capable of remarkably improving the lipid metabolism disorder of mice induced by high fat diet; particularly, the quinoa seedling modified acidic polysaccharide prepared by a directional enzyme digestion technology has the best effect. A scientific theoretical basis and a key processing technology are provided for research and development of functional / healthy quinoa seedling food, and nutritional and high-value utilization of quinoa seedlings is facilitated.

The invention belongs to the technical field of medicines, and particularly provides a novel application of a theaflavin compound in preparation of a product for inhibiting dipeptidyl peptidase-4 (DPP-4), and the theaflavin compound is one or more of theaflavin-3-gallate (TF2A), theaflavin-3 '-digallate (TF3) and theaflavin (TF). The research systematically proves that TF2A, TF3 and TF have new application of inhibiting DPP-4 for the first time: in-vitro enzymology and fluorescence experiments show that theaflavin can inhibit DPP-4 and interact with DPP-4, and molecular docking further shows possible binding configuration and key action sites of theaflavin. In vivo, the activity of DPP-4 in serum and different tissues of high-fat diet mice can be reduced, serum glucagon-like peptide-1 (GLP-1) can be up-regulated, and glycometabolism and inflammatory phenotype can be improved. Therefore, the theaflavin compound disclosed by the invention can be applied to preparation of products for inhibiting DPP-4, and has a good development prospect.

The invention provides a mulberry phellinus linteus strain SH08, mulberry phellinus linteus polysaccharide as well as a preparation method and application of the mulberry phellinus linteus polysaccharide, and belongs to the technical field of biological medicines and functional foods. The mulberry phellinus igniarius strain SH08 provided by the invention is preserved in the China Center for Type Culture Collection on October 11, 2025, the preservation address is No. 299, eight road, Wuchang District, Wuhan City, Hubei Province, the strain preservation number is CCTCC NO: M20252203, and the mulberry phellinus igniarius strain SH08 is named as SanghuangAKSQSH01. The invention also provides a method for preparing high-purity mulberry phellinus linteus polysaccharide (SHP-PS) from sporocarp of the strain, and structural characterization of the polysaccharide. Experiments prove that the SHP-PS can effectively improve non-alcoholic fatty liver disease (NAFLD) induced by high fat diet, and the mechanism of the SHP-PS is closely related to blood fat regulation, liver injury and inflammation reduction, intestinal barrier repair, intestinal flora structure regulation and short-chain fatty acid generation promotion. The invention provides high-quality raw materials and a clear technical scheme for developing novel medicines or functional foods for preventing and treating NAFLD, and has important application value.

Provided is a use of Staphylococcus lentus with an accession number of GDMCC 1.247 in preparation of a composition for preventing and treating insulin resistance or type 2 diabetes. This strain can significantly reduce the weight gain induced by a high-fat diet (HFD), improve the glucose tolerance, promote the insulin secretion, improve the insulin resistance, and significantly improve the immunity and inflammation.

The invention discloses a pediococcus pentosaceus MDL511, which is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.35201, the preservation date is July 11, 2025, and the classification name of the strain is pediococcus pentosaceus. The pediococcus pentosaceus MDL511 has the advantages that the preservation number is CGMCC No.35201, the preservation number is CGMCC No.35201, the preservation date is July 11, 2025, and the classification name of the strain is pediococcus pentosaceus. The pediococcus pentosaceus MDL511 disclosed by the invention can be used for remarkably reducing weight gain and fat growth of mice caused by high fat diet, reducing serum cholesterol, LDL-C (Low Density Lipoprotein Cholesterol) and ALT (Atomic Lymphocyte Transferase) levels and remarkably improving hepatic lesions and fat accumulation caused by high fat diet, so that the MDL511 has a blood fat reducing effect, can be used for preparing blood fat reducing products and weight losing products and has a good development prospect.

This invention discloses a functional Cistanche deserticola polysaccharide, its preparation method, and its applications. Using Cistanche deserticola as raw material, the polysaccharide is first extracted by cell wall disruption using an oxygen free radical-cellulase synergistic technology. The optimal extraction parameters are optimized through single-factor experimental design, overcoming the limitations of traditional methods and achieving efficient, green, and activity-preserving extraction of Cistanche deserticola polysaccharide, providing a high-quality material basis for subsequent research. The Cistanche deserticola polysaccharide extracted by this method can slow down weight gain in obese C57BL / 6J mice induced by a high-fat diet and improve glucose and lipid metabolism disorders. It also induces the production of important biomarkers such as indole, decanoic acid, and nonanoic acid by the intestinal flora of mice. This invention obtains Cistanche deserticola polysaccharides with specific biological activities, achieving high-quality utilization of Cistanche deserticola.

The invention provides application of rosa roxburghii tratt fruit extract in preparation of drugs or health care products for preventing and treating male lower urinary tract symptoms / prostatic fibrosis. The invention belongs to the technical field of biological medicines, and provides application of a roxburgh rose extract in preparation of medicines or health care products for preventing and treating male lower urinary tract symptoms / prostatic fibrosis. Animal experiments prove that the rosa roxburghii tratt extract can effectively improve mouse prostate fibrosis and bladder urinary retention caused by high fat diet and relieve lower urinary tract symptoms by regulating lipid metabolism, resisting inflammation, resisting oxidative stress, regulating sex hormone level and inhibiting a TGF-beta / Smad signal channel.

The present invention provides a composition for alleviating fatty liver disease by using a single or complex extract of Sigesbeckia glabrescens and Luffa cylindrica, the composition exhibiting the activities of inhibiting fat accumulation and inflammation in liver cells without showing toxicity to liver cells, inhibiting fat accumulation and inflammation in liver tissue in high-fat-diet animal models, and increasing the expression of glutathione, which is a strong antioxidant in liver tissue.

The invention discloses an application of probiotic metagen and organic acid in improvement of liver health and colitis, and relates to the technical field of metagen. The invention discovers that both malic acid and / or sebacic acid and acellular supernatant of K56 inactivated bacteria can significantly inhibit the expression of proinflammatory factors, and both have good anti-inflammatory activity. After intervention of K56 acellular supernatant, malic acid and sebacic acid, abnormal liver weight gain of a subject caused by high-fat diet can be relieved, and liver injury caused by the high-fat diet is relieved. Therefore, development of sebacic acid, malic acid or mixed organic acid of malic acid and sebacic acid has a good application prospect in preparation of products for improving liver health. In addition, after intervention of malic acid or sebacic acid, the basic phenotype of the DSS-induced colitis of the test body is relieved. The invention has a good application prospect for developing and preparing products for preventing or treating acute colitis or ulcerative colitis.

This invention discloses a traditional Chinese medicine composition, preparation method, and application with lipid-lowering and intestinal flora-regulating effects, belonging to the field of traditional Chinese medicine technology. The raw material components are: 10-20 parts mulberry leaf, 10-20 parts immature bitter orange, 10-20 parts plantain, 8-15 parts lotus leaf, 8-16 parts medicated leaven, and 8-15 parts poria cocos. Based on the etiology and pathogenesis of obesity, this invention adopts a formula based on the principles of eliminating dampness and phlegm, lowering lipids and clearing turbidity. In addition to changing the obese phenotype, it focuses on balancing the body's internal organs and blood, strengthening the spleen and replenishing qi, resolving phlegm and eliminating dampness, supplemented by promoting qi circulation and digestion, lowering lipids and eliminating phlegm, thereby regulating the body's overall function, accelerating the decomposition of excess fat, and achieving the goal of weight loss by lowering lipids and regulating intestinal flora. Pharmacological experiments have shown that oral administration significantly improves weight gain and liver lipid accumulation induced by a high-fat diet in rats, resulting in clearer liver cord structure, denser cell arrangement, reduced lipid vacuolation and ballooning degeneration, and altering the composition and function of the intestinal microbiota.

The application discloses a functional tea polysaccharide as well as a preparation method and application thereof. The tea polysaccharide is prepared by using coarse old tea leaves as raw materials, and the raw materials are pretreated by supermicronization and dewaxing and small molecule impurities, and then are extracted by adopting cellulase-papain compound wall breaking, and further treated by adopting hydrogen peroxide, so that the tea polysaccharide with high yield and strong biological activity is obtained. The tea polysaccharide extracted by the method can slow down the weight increase of obese C57BL / 6J mice caused by high-fat diet, improve glycolipid metabolism disorder, and make db / m mice intestinal flora metabolize to produce new functions of important biomarkers such as indole, so that the high-quality reuse of coarse old tea leaves is realized.

The invention belongs to the technical field of biological medicine, and provides a human umbilical cord mesenchymal stem cell preparation and application thereof, the preparation comprises human umbilical cord mesenchymal stem cells, ginsenoside Rg3 and a medicinal carrier; the medicinal carrier is a phosphate buffer solution; according to the application, 1 * 10 < 6 > HUCMSCs pretreated by Rg3 are subjected to caudal vein injection on a T2DM mouse model induced by high fat diet combined with STZ, the curative effect and mechanism are verified by combining OGTT, IPITT, serum biochemical detection, HE / PAS tissue staining, q-PCR and other technologies, and finally the purposes of improving glycometabolism of the T2DM mouse, repairing liver / kidney / pancreas target organ injuries, protecting pancreas islet beta cell functions, reducing pancreas islet beta cell functions, reducing pancreas islet beta cell functions, reducing pancreas islet beta cell functions, reducing pancreas islet beta cell functions and the like are achieved. And a theoretical basis is provided for accurate intervention of T2DM by activating an IGF-1R / PI3K-AKT signal channel and regulating and controlling the expression of a glycometabolism-related gene.

The invention belongs to the technical field of functional microorganism application, and particularly relates to a novel lipid-lowering peptide derived from a probiotic thallus and application thereof, the novel lipid-lowering peptide is a crushed substance derived from a probiotic lactobacillus plantarum thallus, and the molecular weight of the novel lipid-lowering peptide is less than 3kDa. And two key polypeptides APGFGDR (AP7) and TESGAFGR (TE8) are identified from the components, and can specifically inhibit the activities of pancreatic lipase and pancreatic cholesterol esterase. The extracted thallus peptide can be efficiently combined with cholate to inhibit the formation of cholesterol micelles, and has a remarkable inhibiting effect on pancreatic lipase and pancreatic cholesterol esterase. Animal experiments show that the mycopeptide can effectively improve lipid metabolism disorder induced by high fat diet, inhibit weight gain, reduce serum and liver lipid levels and relieve fatty degeneration and inflammation of the liver. The lipid-lowering peptide disclosed by the invention is high in safety and multi-target in action, and can be used for preparing functional products for preventing or treating metabolic diseases such as obesity, hyperlipidemia and the like.

The invention relates to the field of microorganisms, and discloses application of aspergillus cristatus in preparation of a medicine for preventing and / or treating hyperglycemia and / or hyperlipidemia, and the preservation number of the aspergillus cristatus is CGMCC No.41727. The aspergillus cristatus provided by the invention can degrade cholesterol, has the activity of degrading cholesterol and sugar-related enzymes, can relieve the symptoms of hyperlipidemia and hyperglycemia of high-fat diet mice, and has an application prospect in drugs for preventing and / or treating hyperglycemia and / or hyperlipidemia.

The invention discloses compound safflower tea capable of reducing blood lipid. The compound safflower tea consists of the following components: 0.19 to 0.21 g of safflower, 0.195 to 2.050 g of American ginseng, 0.90 to 1.10 g of green tea, 1.10 to 1.20 g of hawthorn and 1.35 to 1.45 g of lotus leaf. According to the present invention, the C57BL / 6J mouse is subjected to the lipid-lowering experiment by using the safflower as the main material and using the American ginseng, the green tea, the hawthorn and the lotus leaf as the auxiliary materials, and the result shows that the safflower lipid-lowering tea can significantly reduce the levels of serum total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-C), can improve the liver fatty degeneration and the inflammatory reaction, and can alleviate the intestinal injury caused by the high fat diet; animal behavior experiments including Y maze, open field experiments and new object recognition experiments are used to verify that the safflower lipid-lowering tea has an improvement effect on mouse cognitive impairment caused by dyslipidemia.

The application discloses an application of lactobacillus reuteri BNCC186563 in prevention and improvement of related diseases caused by high-fat diet and belongs to the technical field of microorganisms. It is found that the lactobacillus reuteri BNCC186563 can synergistically activate a PPAR alpha signal pathway and remodel a glycerophospholipid metabolism network, and the lactobacillus reuteri BNCC186563 can be used as a potential medicine, health care product and functional food for preventing and improving related diseases caused by high-fat diet, such as obesity, impaired glucose tolerance, insulin resistance, abnormal lipid metabolism, liver lipid accumulation, liver damage, inflammation and hyperlipidemia.

The invention belongs to the technical field of biomedicine, and particularly relates to a method for detecting potential biomarkers of myocardial of an HFpEF mouse based on non-targeted metabonomics, which comprises the following steps: constructing an HFpEF mouse model by combining high fat diet with L-NAME, setting a conventional feeding control group, monitoring myocardial glucose metabolism through longitudinal [18F] FDG PET / CT, collecting myocardial tissues, and performing non-targeted metabonomics detection. And screening differential metabolites through Foldchange greater than or equal to 1.2 or less than or equal to 0.83 and p less than 0.05, and carrying out correlation analysis on the differential metabolites and [18F] FDG SUVmean to obtain 25 potential biomarkers. According to the method, the steps are clear and repeatable, the marker is directly related to myocardial energy metabolism, the diagnosis specificity is improved, and a support is provided for HFpEF targeted therapy research and development and molecular mechanism research.

The application discloses a liver-protecting EPA fish oil composition for high-fat-diet people and relates to the technical field of functional health foods and dietary supplements; the application takes high-purity EPA fish oil as a core active ingredient and adopts scientific proportioning and refining processes, so that the excellent effect of EPA in regulating liver lipid metabolism is ensured, and meanwhile, the composition of the application further adds natural active ingredients which have synergistic liver-protecting effects with EPA, so that a double-path liver-protecting system is formed, liver lipid metabolism is regulated, liver cell structure is repaired, oxygen free radicals are removed, and inflammatory reactions are inhibited, and thus, comprehensive protection of the liver is realized.

This invention belongs to the field of traditional Chinese medicine and discloses the application of total saponins extract of *Abrus precatorius* in the preparation of drugs for treating metabolic-associated fatty liver disease (MAFLD). Through experiments in high-fat diet-induced MAFLD mice, this invention demonstrates that total saponins of *Abrus precatorius* can protect the liver from a series of damages caused by excessive lipid accumulation. The potential mechanisms include regulating lipid metabolism through the PPAR and AMPK signaling pathways, and modulating the balance of gut microbiota. These findings provide a solid research foundation and empirical evidence for the potential application of total saponins of *Abrus precatorius* in the treatment of MAFLD.

The invention discloses a traditional Chinese medicine composition, belongs to the technical field of traditional Chinese medicines, and aims to solve the problems of dyslipidemia and liver lipid deposition caused by chronic high fat diet. The composition comprises two formulas, wherein the formula A consists of astragalus membranaceus, lucid ganoderma and schisandra chinensis according to the weight ratio of 1: 1: 1; the formula B is composed of schisandra chinensis and liquorice according to the weight ratio of 3: 1, and can significantly activate an NRF2 / ARE pathway, up-regulate expression of antioxidant genes such as NQO1 and HO-1, inhibit H2O2-induced ROS generation and cell apoptosis, and improve related symptoms from the molecular level; meanwhile, the provided preparation method can improve the solubility of active ingredients and the intestinal absorption efficiency, avoids ingredient degradation caused by high-temperature extraction, ensures long-acting stable release of the medicine in vivo, and is mainly used for improving dyslipidemia and liver lipid deposition caused by chronic high-fat diet.

This invention provides *Pediococcus lactis* SHI03 and its application in alleviating insulin resistance and type 2 diabetes, belonging to the field of microbial technology. This invention provides *Pediococcus lactis* SHI03, with accession number CCTCC No: M 20242686, and confirms that this strain possesses in vitro α-glucosidase inhibitory activity, exhibiting excellent probiotic and hypoglycemic effects. This invention further provides microbial products containing *Pediococcus lactis* SHI03, including *Pediococcus lactis* SHI03 fermentation broth, *Pediococcus lactis* SHI03 fermentation supernatant, and *Pediococcus lactis* SHI03 cells, and their applications in alleviating high-fat diet-induced insulin resistance and reducing fasting blood glucose in type 2 diabetic mice.

The present invention relates to the use of LAT1 inhibitors in the preparation of drugs for treating atherosclerosis, belonging to the field of pharmaceutical technology. To solve the clinical problem that there is still a relatively high residual risk in advanced atherosclerosis under the current treatment strategies, the present invention provides the use of LAT1 inhibitors in the preparation of drugs for treating atherosclerosis. The present invention has confirmed that LAT1 inhibitors delay the progression of atherosclerosis by inhibiting the entry of leucine into macrophages, reducing plaque area and necrotic core; at the same time, LAT1 inhibitors can also enhance the mitochondrial function of macrophages, increase fatty acid oxidation, reduce lipid deposition in atherosclerotic plaques, increase the stability of atherosclerotic plaques, delay the development of atherosclerosis induced by a high-fat diet, and can be applied to patients in whom the use of other types of anti-atherosclerotic drugs is limited due to diseases such as combined gastrointestinal bleeding, aortic aneurysm or tumor.

The invention discloses an establishment method and application of an animal model of a mental stress exacerbation metabolic disease, and belongs to the technical field of biomedicine. The method comprises the following steps: selecting SPF-level C57BL / 6J mice, randomly grouping the mice, adaptively feeding the mice for 7 days, and then periodically and cyclically modeling the mice for four cycles in total. Each cycle comprises two weeks of 60% high fat diet feeding and one week of common maintenance feed diet; 7-day chronic social failure stress modeling is carried out during a common feed diet maintaining period. According to the method disclosed by the invention, the mouse model capable of effectively simulating clinical mental stress exacerbation glycolipid metabolism disorder is constructed, and the blank of a model for inducing glycolipid metabolism disorder by combining mental stress and dietary factors is filled. The mouse model provided by the invention is helpful for promoting the pathogenesis of metabolic diseases and researching potential therapeutic targets.

The invention relates to application of procyanidine B2 in preparation of a product for delaying or treating senescence induced by high fat diet, and relates to the technical field of biological medicine. Long-term animal experiments prove that long-term supplement of procyanidine B2 can significantly prolong the life of high-fat diet mice, regulate intestinal flora and comprehensively improve healthy life indexes such as cognition, athletic ability and body weakness states, a foundation is laid for research and development of products for treating senescence induced by high-fat diet, and the procyanidine B2 has a broad application prospect in treatment of senescence induced by high-fat diet. Good application and popularization prospects are realized.